• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cytek Biosciences, Inc. - Common Stock (NQ:CTKB)

    4.130 -0.050 (-1.20%)
    Streaming Delayed Price Updated: 10:57 AM EDT, Aug 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cytek Biosciences, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter
    World’s First Enhanced Small Particle (ESP™) Detection Sorter Enables Effective Content Isolation; Opens Door to Scientific Discoveries 
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Preview: Cytek Biosciences's Earnings ↗
     
    Via Benzinga
    News headline image
    Nasdaq Surges Over 500 Points; Johnson Controls Earnings Top Views ↗
     
    Via Benzinga
    News headline image
    Gold Down Over 2%; CVS Health Shares Jump After Q3 Results ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Mercury Systems Posts Strong Results, Joins ArcBest, Tesla, Kennametal, Qualys And Other Big Stocks Moving Higher On Wednesday ↗
     
    Via Benzinga
    News headline image
    Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe
    Industry Leaders to Explore Cytek’s Advanced Cell Analysis Solutions at ICCS and ESCCA 
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
    Certification Emphasizes Unwavering Commitment to Quality and Is an Essential Step for U.S. Clinical Market Entry 
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    CTKB Stock Earnings: Cytek Biosciences Misses EPS, Misses Revenue for Q2 2024 ↗
    CTKB stock results show that Cytek Biosciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    News headline image
    Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm
    Expanding Capabilities and Streamlining Experimental Workflows 
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek Biosciences Announces $50 Million Stock Repurchase Program
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
    New Enhanced Small Particle (ESP™) Detection Option for Cytek Northern Lights™ and Cytek Aurora™ Systems Expands Capabilities of Small Particle Research 
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    CTKB Stock Earnings: Cytek Biosciences Misses EPS, Beats Revenue for Q1 2024 ↗
    CTKB stock results show that Cytek Biosciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    News headline image
    Cytek Biosciences Reports First Quarter 2024 Financial Results
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
    Company to Conduct Educational Workshops and Tutorials at CYTO and AAI’s IMMUNOLOGY2024 
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    CTKB Stock Earnings: Cytek Biosciences Beats Revenue for Q4 2023 ↗
    CTKB stock results show that Cytek Biosciences beat on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    News headline image
    Cytek® Biosciences Names William McCombe Chief Financial Officer
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday ↗
    U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday. 
    Via Benzinga
    Topics Stocks
    News headline image
    Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
    Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
    Via Benzinga
    News headline image
    Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek Biosciences to Participate in Upcoming Investor Conferences
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
    Cytek’s Cutting-Edge Spectral Flow Cytometry Technology, Specialized Staff, Tools and Solutions Set New Benchmarks for Cell Analysis 
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.